TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8270989
Drug: Etoposide at
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide at 20, 25, or 30 mg/m2/d infused continuously for 14 days (336 hours) with a 10-mg/m2 bolus and cisplatin 30 mg/m2 on chemotherapy days 1, 2, and 3
Study: 8270989
Drug: Etoposide at
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide at maximum-tolerated dose (MTD) of 25 mg/m2/d
Study: 8270989
Drug: Etoposide with
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide with Css greater than 1 microgram/mL
Study: 10433587
Drug: Chloroquine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (300 mg weekly) + Primaquine (30 mg daily)
Study: 2200299
Drug: Lignocaine 20
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 20 mg pretreatment, followed by induction with propofol plus saline 2 ml
Study: 2200299
Drug: Lignocaine 40
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 40 mg pretreatment, followed by induction with propofol plus saline 2 ml
Study: 2200299
Drug: Saline pretreatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline pretreatment, followed by induction with propofol plus lignocaine 20 mg
Study: 2200299
Drug: Saline pretreatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline pretreatment, followed by induction with propofol plus lignocaine 40 mg
Study: 2200299
Drug: Saline pretreatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline pretreatment, followed by induction with propofol plus saline 2 ml
Study: 7389253
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg indacrinone alone
Study: 7389253
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg indacrinone + 2.5 mg amiloride
Study: 7389253
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg indacrinone + 5 mg amiloride
Study: 7389253
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg indacrinone
Study: 27564775
Drug: Thymopentin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (2 mg per day, 15 days, three courses in total)
Study: 27564775
Drug: Regular therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular therapy with thymopentin
Study: 29722166
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus placebo gel
Study: 15976585
Drug: Lotrafilcon A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotrafilcon A lenses (daily wear)
Study: 15976585
Drug: Balafilcon A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balafilcon A lenses (daily wear)
Study: 11712772
Drug: Web-based software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based software for site training, study documentation, subject recruitment, randomization, medication dispensing, and management procedures
Study: 7999596
Drug: Etretinate treatment
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretinate treatment
Study: 2626514
Drug: Fluphenazine (mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine (mixed D1/D2 dopamine antagonist)
Study: 776193
Drug: Diazepam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.3 mg/kg i.v. with food intake at 3 hours post-injection
Study: 776193
Drug: Diazepam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.3 mg/kg i.v. with food intake at 7 hours post-injection
Study: 776193
Drug: Diazepam 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.15 mg/kg i.v. with rapid injection
Study: 6785095
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 40 microgram/kg via 30 min i.v. infusion
Study: 26974423
Drug: FAST treatment
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAST treatment (20 mL/kg of crystalloid over 10 min)
Study: 26974423
Drug: SLOW treatment
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLOW treatment (20 mL/kg of crystalloid over 30 min)
Study: 26974423
Drug: FAST treatment
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAST treatment
Study: 26974423
Drug: SLOW treatment
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLOW treatment
Study: 26974423
Drug: Both FAST
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both FAST and SLOW treatments
Study: 1490141
Drug: Vitamin B1
Normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B1 (100 mg/day)
Study: 25363189
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (500 mg/day)
Study: 22267420
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg daily before bedtime for 30 days
Study: 10453964
Drug: 300-mg abacavir
Normalized name: abacavir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg abacavir hemisulfate tablet (oral)
Study: 10453964
Drug: 300-mg abacavir
Normalized name: abacavir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg abacavir hemisulfate tablet with food
Study: 10453964
Drug: abacavir (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: abacavir (various formulations)
Study: 31190735
Drug: Anifrolumab (fully
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anifrolumab (fully human monoclonal antibody targeting IFNAR1)
Study: 25483366
Drug: Calcifediol (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcifediol (140 μg weekly)
Study: 25483366
Drug: Cholecalciferol (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (140 μg weekly)
Study: 8287583
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2b (IFN) therapy for 24 weeks
Study: 2250886
Drug: Control eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control eye (no treatment)
Study: 28141897
Drug: Everolimus (EVR)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (EVR) with low-dose tacrolimus (LTac) and prednisone
Study: 25721183
Drug: Sertraline (SRT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (SRT, n = 133)
Study: 25721183
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT, n = 139)
Study: 25721183
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both (COMB, n = 140)
Study: 25721183
Drug: Pill Placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill Placebo (PBO, n = 76)
Study: 23937345
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) augmentation of cognitive behavioral therapy (CBT)
Study: 23937345
Drug: Placebo augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo augmentation of cognitive behavioral therapy (CBT)
Study: 21521468
Drug: Nafamostat mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat mesilate (NM) 0.02 mg/kg
Study: 14536040
Drug: Prototype Mk
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype Mk IV implant (test)
Study: 14536040
Drug: Brånemark implant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brånemark implant (control)
Study: 29610765
Drug: Both test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both test and control implants
Study: 9002829
Drug: Test implants
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test implants
Study: 10936478
Drug: Third-generation thrombolytic
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation thrombolytic agents (monteplase, tenecteplase, reteplase, lanoteplase, pamiteplase, staphylokinase)
Study: 10936478
Drug: Second-generation agent
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation agent (alteplase)
Study: 10936478
Drug: Third-generation thrombolytic
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation thrombolytic agents
Study: 6837243
Drug: Lidocaine 2
Normalized name: lidocaine 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2 mg/kg body weight
Study: 30014662
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus rehabilitation training plus acupuncture (observation 2 group)
Study: 30014662
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus rehabilitation training (observation 1 group)
Study: 30014662
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone (control group)
Study: 25689448
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1,600 mg
Study: 25689448
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1,200 mg
Study: 22029225
Drug: Esomeprazole formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole formulation 1
Study: 22029225
Drug: Esomeprazole formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole formulation 2
Study: 14736130
Drug: Zaleplon (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon (10 mg)
Study: 15648985
Drug: Diclofenac 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 15 mg
Study: 11329407
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day of sustained‐release bupropion
Study: 3307309
Drug: Insulin at
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin at 40 IU/ml (U40)
Study: 3307309
Drug: Insulin at
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin at 100 IU/ml (U100)
Study: 27054798
Drug: Vaginal hysterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal hysterectomy with native tissue vault suspension
Study: 27054798
Drug: Mesh hysteropexy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesh hysteropexy suspension
Study: 26271057
Drug: Control of
Normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control of 6 risk factors (no smoking, non-HDL cholesterol <130 mg/dl, triglycerides <150 mg/dl, blood pressure systolic <130 mm Hg; diastolic <80 mm Hg, glycosylated hemoglobin <7%)
Study: 23675549
Drug: Coadministered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministered treatment (ivermectin/albendazole/azithromycin)
Study: 23675549
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ivermectin/albendazole with azithromycin 1 week later)
Study: 17661038
Drug: Glufosfamide 4,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glufosfamide 4,500 mg/m(2) + Gemcitabine 1,000 mg/m(2)
Study: 12936918
Drug: Dietary fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fish oil (0.3, 1, and 2 g eicosapentaenoic acid plus docosahexaenoic acid/d for 4 consecutive weeks)
Study: 12936918
Drug: Antioxidant cosupplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant cosupplementation (200 microg Se, 3 mg Mn, 30 mg RRR‐alpha‐tocopheryl succinate, 90 mg ascorbic acid, 450 microg vitamin A)
Study: 9106811
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium amytal (SA)
Study: 3763944
Drug: BN 52063
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BN 52063 (PAF antagonist) at a dose of 80 mg
Study: 3763944
Drug: BN 52063
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BN 52063 (PAF antagonist) at doses of 20, 40, 80, and 120 mg
Study: 29735455
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 0.2% ropivacaine injection at acupoints Hegu and Sanyinjiao
Study: 29735455
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection at acupoints Hegu and Sanyinjiao
Study: 24164308
Drug: UVA1 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UVA1 treatment (medium-dose, four times weekly for 3 months)
Study: 21785863
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 50 mg/kg clofibrate and phototherapy
Study: 15634716
Drug: NETE 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: NETE 200 mg plus TU 1000 mg every 8 wk
Study: 15634716
Drug: NETE 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: NETE 200 mg plus TU 1000 mg every 12 wk
Study: 15634716
Drug: TU 1000
Normalized name: PEMRYDI RTU 1000 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TU 1000 mg plus placebo every 12 wk
Study: 4073878
Drug: Tetracycline hydrochloride
Normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline hydrochloride at 0.5 g every 6 h or doxycycline at 100 mg every 12 h for 30 days plus 1 g of streptomycin a day for 21 days (Group A)
Study: 4073878
Drug: Rifampin at
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin at 15 mg/kg per day in a single morning dose plus 100 mg of doxycycline every 12 h for 30 days (Group B)
Study: 31737351
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) delivered in 2 face-to-face sessions and 4 phone sessions
Study: 29485323
Drug: Multi-ingredient dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-ingredient dietary preworkout supplement
Study: 25283252
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of oral collagen peptide (CP) for 4 weeks
Study: 22484523
Drug: 300 mL
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mL of alcohol-free wine
Study: 15949594
Drug: PVU group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVU group (2 courses of cisplatin 80 mg/m2, i.v. x 1 (day 1), vindesine 3 mg/m2, i.v. x 1 (days 1 and 8) and UFT 400 mg/day, p.o. for 2 years)
Study: 15949594
Drug: UFT group
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT group (UFT 400 mg/day, p.o. for 2 years)
Study: 10458542
Drug: Lentinan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinan (2 mg) administered 7 days before surgery
Study: 7791055
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac (Acular)
Study: 7791055
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac (Voltaren)
Study: 7791055
Drug: Control medication
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control medication (HypoTears)
Study: 7791055
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen #3
Study: 2225696
Drug: Acetaminophen (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (2.7 gm/day)
Study: 3144541
Drug: Amoxycillin 3
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 3 g
Study: 389351
Drug: Ampicillin 3
Normalized name: ampicillin 389 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 3 g plus probenecid 1 g
Study: 21255399
Drug: Social-skills training
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social-skills training and parental training plus standard treatment
Study: 20930708
Drug: Evening ingestion
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening ingestion of ACE inhibitors (benazepril, captopril, enalapril, lisinopril, perindopril, quinapril, ramipril, spirapril, trandolapril)
Study: 20930708
Drug: Chronotherapy (timing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronotherapy (timing of treatment to body rhythms)
Study: 16948837
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (hydrogel)
Study: 9167508
Drug: Subanesthetic doses
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanesthetic doses of ketamine
Study: 7948468
Drug: Glucose ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose ingestion (100 mg)
Study: 2893080
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg thrice a day
Study: 28279123
Drug: Oral clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clarithromycin (7.5 mg/kg, twice a day)
Study: 18942898
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg bolus of pantoprazole followed by continuous infusion of 8 mg/h for 72 hours (group 0)
Study: 18942898
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of pantoprazole administered intravenously daily (group 1)
Study: 2445316
Drug: Flecainide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (200 to 400 mg per day)
Study: 2445316
Drug: Amiodarone (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (800 to 400 mg per day)
Study: 24780069
Drug: G-G-A-A-C-C haplotype
Normalized name: penicillin G Prefilled Syringe [Bicillin L-A]
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-G-A-A-C-C haplotype (carrying rs964184-G-allele)
Study: 24780069
Drug: A-C-G-G-C-C haplotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-C-G-G-C-C haplotype (carrying rs964184-C-allele)
Study: 24780069
Drug: A-C-A-G-T-C haplotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-C-A-G-T-C haplotype (carrying rs964184-C-allele)
Study: 22375972
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (15 mg per 16 hours)
Study: 23483627
Drug: istradefylline 20
Normalized name: istradefylline 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: istradefylline 20 mg/day
Study: 18519872
Drug: istradefylline 60
Normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: istradefylline 60 mg/day
Study: 2140748
Drug: Polyvalent oral
Normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvalent oral bacterial vaccine
Study: 343312
Drug: Panidazole (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panidazole (1.0 - 2.0 g per day for 6 days)
Study: 343312
Drug: Metronidazole (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1.0 - 2.0 g per day for 6 days)
Study: 343312
Drug: Panidazole (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panidazole (1.0 g per day for 7 days)
Study: 343312
Drug: Panidazole (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panidazole (1.0 g per day for 10 days)
Study: 31968697
Drug: Dietary advice
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary advice including green vegetables five times per week, beef three times per week, 300 mL whole milk per day, and whole dairy butter on bread every day plus standard supportive care.
Study: 22402673
Drug: Oral 150
Normalized name: carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 150 mg monthly ibandronate
Study: 11920413
Drug: Pamidronate 10
Normalized name: pamidronate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 10 mg
Study: 11480815
Drug: 0.1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% chlorhexidine (CHX) solution
Study: 11480815
Drug: Amine fluoride/stannous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride/stannous fluoride (ASF) solution
Study: 8035399
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received treatment after 3 months.
Study: 2538577
Drug: CEV regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEV regimen (cyclophosphamide 1,000 mg/m2 IV day 1, vincristine 1.4 mg/m2 IV day 1, etoposide 50 mg/m2 IV day 1, followed by etoposide 100 mg/m2/day orally days 2 through 5)
Study: 2538577
Drug: CAV regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV regimen (cyclophosphamide 1,000 mg/m2 IV day 1, vincristine 1.4 mg/m2 IV day 1, doxorubicin 50 mg/m2 IV day 1)
Study: 2538577
Drug: CV regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV regimen (cyclophosphamide 2,000 mg/m2 day 1, vincristine 1.4 mg/m2 IV day 1)
Study: 983073
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pentazocine plus 500 mg acetylsalicylic acid (P + A)
Study: 11724948
Drug: Chlorophyllin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorophyllin (100 mg, three times a day for 4 months)
Study: 7370145
Drug: Meptazinol 100
Normalized name: meptazinol 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 100 mg
Study: 8405626
Drug: Pethidine 75
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 75 mg
Study: 27383377
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg spironolactone (MR antagonist)